The trading price of Dare Bioscience Inc. (NASDAQ:DARE) closed higher on Friday, August 27, closing at $1.74, 0.58% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $1.70 and $1.80. In examining the 52-week price action we see that the stock hit a 52-week high of $3.85 and a 52-week low of $0.94. Over the past month, the stock has gained 14.47% in value.
3 Tiny Stocks Primed to Explode The worlds greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
Weve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Dare Bioscience Inc., whose market valuation is $121.99 million at the time of this writing, is expected to release its quarterly earnings report Nov 10, 2021 – Nov 15, 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.16 per share this quarter, however they have predicted annual earnings per share of -$0.68 for 2021 and -$0.7 for 2022. It means analysts are expecting annual earnings per share growth of 25.30% this year and -2.90% next year.
From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2021 is $1.25 million.
A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Dare Bioscience Inc. No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest DARE has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a Hold, while an average of long term indicators suggests that the stock is currently 50% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned DARE a recommendation rating is 4. Out of them, 0 rate it a Hold, while 4 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Dare Bioscience Inc. (DARE) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that DARE’s price is currently 8.75% off the SMA20 and 9.86% off the SMA50. The RSI metric on the 14-day chart is currently showing 60.06, and weekly volatility stands at 6.16%. When measured over the past 30 days, the indicator reaches 7.00%. Dare Bioscience Inc. (NASDAQ:DARE)’s beta value is currently sitting at 1.69, while the Average True Range indicator is currently displaying 0.10. With analysts defining $3.00-$11.00 as the low and high price targets, we arrive at a consensus price target of $5.50 for the trailing 12-month period. The current price is about -72.41% off the estimated low and -532.18% off the forecast high, based on this estimate. Investors will be thrilled if DARE’s share price rises to $4.00, which is the median consensus price. At that level, DARE’s share price would be -129.89% below current price.
To see how Dare Bioscience Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: DARE stock’s performance was 0.58% in the latest trading, and 61.11% in the past year, while Clovis Oncology Inc. (CLVS) has traded 3.08% on the day and positioned -8.41% lower than it was a year ago. Another comparable company Madrigal Pharmaceuticals Inc. (MDGL) saw its stock close 1.62% higher in the most recent trading session but was down -21.57% in a year. Furthermore, Seagen Inc. (SGEN) showed a decrease of -1.26% on the day while its price kept inclining at 8.24% over the past year. Dare Bioscience Inc. has a P/E ratio of 0. Also in last trading session, the S&P 500 Index has surged 0.88%, while the Dow Jones Industrial also saw a positive session, up 0.69% on the day.
An evaluation of the daily trading volume of Dare Bioscience Inc. (NASDAQ:DARE) indicates that the 3-month average is 9.27 million. However, this figure has increased over the past 10 days to an average of 3.59 million.
Currently, records show that 50.44 million of the company’s shares remain outstanding. The insiders hold 5.57% of outstanding shares, whereas institutions hold 5.00%. The stats also highlight that short interest as of May 27, 2021, stood at 1.28 million shares, resulting in a short ratio of 2.14 at that time. From this, we can conclude that short interest is 2.60% of the company’s total outstanding shares. It is noteworthy that short shares in May were up slightly from the previous month’s figure, which was 1.16 million. However, since the stock’s price has seen 29.85% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
Tell us about you
Find us at the office
Eastmond- Sukel street no. 62, 79540 Hanga Roa, Easter Island
Give us a ring
+74 201 709 645
Mon - Fri, 9:00-15:00